Biosimilars Pricing In Medicare Part D Needs Legislative Fix, Avalere Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Requiring 50% discount for biosimilars in the coverage gap or establishing biosimilar specialty tier with reduced coinsurance could encourage broader take-up, consulting firm suggests.